NanoViricides Receives Regulatory Approval for Phase II MPox Trial in Democratic Republic of Congo
NanoViricides has received regulatory approval to begin Phase II clinical trials for its broad-spectrum antiviral drug NV-387 to treat MPox in the Democratic Republic of Congo, representing a potential breakthrough in antiviral therapy.
NanoViricides, Inc. has received regulatory approval from the Democratic Republic of Congo's ACOREP agency to begin Phase II clinical trials evaluating NV-387 for the treatment of MPox caused by hMPXV infection. The approval marks a significant regulatory milestone for the company's antiviral development program, with the trial set to assess both safety and effectiveness of the experimental treatment.
NV-387 represents a novel approach to antiviral therapy, designed to mimic human cells to trap and destroy viruses. The drug candidate has demonstrated potential as a broad-spectrum antiviral targeting up to 95% of human pathogenic viruses, according to company statements. This broad-spectrum capability could position NV-387 as a transformative treatment in the antiviral field, potentially mirroring the impact antibiotics had on bacterial disease treatment.
Company President and Executive Chairman Anil R. Diwan, PhD, described the regulatory approval as an important milestone in the development of NV-387. The drug is part of NanoViricides' nanoviricide class of drug candidates based on technology licensed from TheraCour Pharma, Inc. The company's business model involves licensing specific antiviral applications from TheraCour, as established at its foundation in 2005.
Beyond the MPox application, NanoViricides plans to develop NV-387 as a treatment for multiple respiratory viral infections including RSV, COVID, Long COVID, and Influenza. The company's development pipeline includes NV-HHV-1 for shingles treatment and programs targeting numerous other viral diseases including herpes, HIV, Hepatitis C, and Ebola. Additional information about the company's programs is available at https://www.nanoviricides.com.
The regulatory approval comes as the Democratic Republic of Congo continues to face challenges with MPox outbreaks, making the development of effective treatments particularly urgent. The Phase II trial represents a critical step in determining whether NV-387 can deliver on its promise as a broad-spectrum antiviral solution. While the company has expressed optimism about the drug's potential, it acknowledges the inherent risks in drug development, noting that successful laboratory results don't guarantee successful clinical outcomes.
NanoViricides holds exclusive worldwide licenses for TheraCour's nanomedicine technology for several specific viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, and various other viral pathogens. The company maintains that its platform technology could revolutionize antiviral treatment approaches if clinical trials prove successful. The latest updates regarding NanoViricides' development programs are available through the company's newsroom at https://ibn.fm/NNVC.